The Advanced Research Projects Agency for Health (ARPA-H) has awarded a new tranche of funds for companies and institutions ...

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...

Roche has halted development on two of its Huntington’s disease prospects, delivering another blow to a patient community that has long awaited new medicines. The Swiss drugmaker explained its ...

Fate Therapeutics has seen improvements in 4 patients with treatment-resistant systemic sclerosis who were dosed with it | ...

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...

Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...

Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...

The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...

Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates (ADCs) using ...

Diagnostics specialist Beckman Coulter has expanded its portfolio of Alzheimer’s disease diagnostics by earning a ...